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Viewpoints
For >10 years ago, an unexpected role for the trans-forming growth factor-β cytokine pathway has been 
put forward in driving thoracic aortic aneurysms and dis-
sections. Here, we reassess the evidence for a detrimental 
transforming growth factor-β overdrive in thoracic aortic 
aneurysms and dissections. In our view, most of the avail-
able mechanistic data argue against this theory.
Syndromic thoracic aortic aneurysms and dissections 
(TAADs) develop in patients with connective tissue disorders 
because of genetic mutations that affect structural components 
of the extracellular matrix and the cell contractile machin-
ery. Early pathogenic hypotheses attributed the aortopathy 
to structural failure of the aortic tissue. Over 14 years ago, 
Neptune et al,1 Habashi et al,2 and Lindsay and Dietz3 pro-
posed a novel hypothesis to explain how fibrillin-1 (FBN1) 
mutations in Marfan syndrome (MFS) lead to pulmonary 
emphysema and aortic aneurysm and pointed to increased 
transforming growth factor-β (TGFβ) activation as the culprit 
mechanism. This constituted a major paradigm shift, and a 
new hope emerged that the life-threatening manifestations of 
MFS might be prevented by a simple medical treatment, losar-
tan, shown to prevent the disease in mice through its TGFβ-
antagonizing properties.2
In 2010, we serendipitously discovered that TGFβ neu-
tralization in mice treated with AngII (angiotensin II) unex-
pectedly induced fatal aortic dissections.4 Despite differences 
in the mouse models, the critical vasculoprotective role of 
TGFβ in our experiments highly contrasted with the reported 
pathogenic role of TGFβ in MFS and Loeys–Dietz syndrome 
(LDS), leading us to question the validity of the previous as-
sumptions. Moreover, recent clinical testing of the concept 
in MFS patients failed to show any benefit of losartan over 
placebo or β-blockade.5 Thus, the time has come for a reas-
sessment of the scientific evidence that supports a causal role 
for increased TGFβ signaling in TAADs.
What Is the Evidence for Increased TGFβ 
Signaling in TAADs?
Marfan Syndrome
The paradigm stipulates that FBN1 mutations are responsible 
for increased TGFβ signaling through increased bioavailabil-
ity of TGFβ.
FBN1 contains 8-cysteine domains similar to those found 
in LTBPs (latent TGFβ binding proteins) and directly interacts 
with LTBP1. An in vitro study showed that a recombinant FBN1 
fragment (PF10) can interact with N-terminal FBN1 (which 
contains the hybrid domain required for binding to LTBP1) and 
inhibits its association with LTBP1.6 In cell layer extracellular 
matrix, PF10 releases endogenous TGFβ1, which stimulates 
SMAD2 phosphorylation (P-SMAD2). Because FBN1 muta-
tions may increase proteolytic susceptibility of microfibrils, 
the above-described mechanism was proposed to account for 
increased TGFβ activity in MFS. However, those studies used 
engineered FBN1 fragments, which might not be relevant to 
FBN1 fragments generated in vivo. In fact, tissue-purified mi-
crofibrils did not increase P-SMAD2.6 Moreover, direct disrup-
tion of FBN1/LTBP interaction through deletion of the hybrid 1 
region of FBN1 did not induce any MFS phenotype.7
The strongest evidence for increased TGFβ activity in 
MFS seems to be (1) the demonstration of increased TGFβ 
signaling in the lungs of MFS mice using a GFP reporter un-
der the control of TGFβ-responsive promoter elements1 and (2) 
the detection of a TGFβ signature (increased TGFβ ligands, 
P-SMAD2/3, and TGFβ-responsive genes) in MFS tissues.2 
Yet, no evidence is available that the TGFβ reporter activity 
can be abrogated by an anti-TGFβ antibody. TGFβ-responsive 
promoter elements are SMAD3/SMAD4-binding sequences 
and may well respond to TGFβ-independent SMAD activation. 
This is likely given that increased activation of SMAD2/3 can 
occur independently of TGFβ in MFS tissues.8 Furthermore, 
the increased aortic TGFβ signature tends to occur in advanced 
stages of disease development, suggesting that it is a com-
pensatory, rather than a primary, detrimental process. Indeed, 
aortic TGFβ signaling is unaltered in young Fbn1C1039G/+ MFS 
mice, despite the presence of early signs of aortic disease.9
Mutations in the TGFβ Signaling Pathway
LDS-associated mutations (TGFBR1, TGFBR2, TGFB2, 
TGFB3, SMAD3, and SMAD4) are expected to disrupt TGFβ 
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signaling.3 However, this explanation has been challenged 
based on a tissue signature suggestive of increased TGFβ sig-
naling.10 In fact, there is no evidence that this signature can be 
abrogated by neutralization of TGFβ. As in MFS, the TGFβ 
signature is detected only at late disease stages and is absent 
in aortas of young LDS animals.10 Moreover, vascular smooth 
muscle cells (VSMCs) from aortas of LDS mice displayed re-
duced, not increased, signaling in response to TGFβ.10
Does Increased TGFβ Activity Promote 
TAADs?
Marfan Syndrome
New data suggest that the original finding of reduced aortic 
aneurysm in Fbn1C1039G/+ MFS mice after TGFβ neutralization2 
may not be reproducible. Cook et al11 found that treatment of 
Fbn1C1039G/+ mice with 1D11 anti-TGFβ antibody was associ-
ated with an appreciable trend toward disrupting (rather than 
preserving) aortic tissue architecture. 1D11 treatment also 
dramatically exacerbated the aortopathy in the severe Fbn1mgR/
mgR
 model, when initiated at postnatal day 16.11 Intriguingly, 
the authors suggested an improvement in survival when 1D11 
was initiated at day 45. However, the Kaplan–Meier curves 
indicate that the difference in survival was already present 
before the initiation of 1D11 injections, with survival curves 
being almost parallel after treatment initiation.
Reduced aortopathy in Fbn1mgR/mgR mice under Ltbp3−/− 
background has been attributed to normalization of TGFβ ac-
tivity.12 However, this is a speculation given that the authors 
were unable to detect differences in activity or signaling using 
antibodies that recognize either active TGFβ or phosphory-
lated SMADs in Ltbp3−/− mice.13
Genetic manipulations of TGFβ signaling support a 
protective role of TGFβ in MFS. MFS aortopathy is aggra-
vated in Fbn1C1039G/+ mice with disrupted canonical SMAD4 
(Smad4+/−).14 This was interpreted as resulting from a detri-
mental increase of TGFβ-dependent noncanonical pathway.14 
However, no data were presented to show that blockade of 
TGFβ abolishes the aortopathy of Fbn1C1039G/+ Smad4+/− mice. 
In contrast, further reduction of TGFβ2 using Tgfb2+/− mice15 
or deletion of Tgfbr2 in VSMCs9,16 substantially aggravated 
the aortopathy of Fbn1C1039G/+ mice.
Mutations in the TGFβ Signaling Pathway
If TGFβ signaling is pathogenic in LDS, TGFβ neutralization 
should prevent the disease. However, treatment of Tgfbr2G357W/+ 
mice with 1D11 antibody failed to rescue the aortic pheno-
type.10 As in MFS, the disease was prevented by losartan, and 
treatment efficacy correlated with reduced TGFβ1 expression 
and P-SMAD2. However, losartan is not a selective TGFβ 
antagonist, and its protective effects in LDS (or MFS) mice 
cannot be used as a proof of the pathogenic role of TGFβ 
signaling in those settings. Actually, other studies strongly 
suggest that direct blockade of residual TGFβ signaling in 
LDS would be detrimental. Deletion of Tgfbr2 selectively 
in VSMCs (Myh11CreERT2 Tgfbr2fl/fl) induces severe TAAD.16 
Although the model is not a true LDS model, the phenotype is 
consistent with that of the Tgfbr2G357W/+ strain.10 Interestingly, 
TGFβ neutralization in Myh11CreERT2 Tgfbr2fl/fl mice aggravat-
ed the disease and induced fatal aortic ruptures.16
Other TAADs
Elastogenesis is altered in both Fibulin-4– and Fibulin-5–
deficient mice. However, only Fibulin-4–deficient mice devel-
op aortic aneurysm. In contrast to Fibulin-5, Fibulin-4 plays 
an additional role in targeting the enzyme lysyl oxidase (LOX) 
to microfibrils. Given the reported role of LOX in TGFβ in-
activation, it has been argued that reduced LOX activity may 
be responsible for aortic aneurysm in Fibulin-4–deficient 
mice through increased TGFβ activation.3 However, neutral-
ization of TGFβ signaling does not prevent the aortic dis-
ease of LOX-deficient embryos; it instead induces numerous 
hemorrhages.17 Thus, the aortic phenotype of LOX-deficient 
or Fibulin-4–deficient mice cannot be attributed to increased 
TGFβ signaling.
Shprintzen–Goldberg syndrome is caused by mutations 
in SKI and shares features with MFS and LDS. Most of the 
mutations are missense mutations within the R-SMADs, sug-
gesting a role for altered TGFβ signaling.18 Patient fibroblasts 
seem to display an increased TGFβ signature.18 However, 
the increased P-SMAD2/3 and P-ERK were seen in vitro in 
the absence of TGFβ, and intriguingly, responses to TGFβ2 
stimulation (increase from baseline) were similar between the 
patient and control fibroblasts.18 Moreover, SKI knockdown 
does not necessarily impair TGFβ-dependent transcriptional 
responses,19 and there is currently no evidence that abroga-
tion of TGFβ signaling rescues the phenotype of Shprintzen–
Goldberg syndrome. Furthermore, SKI interacts with and 
regulates many other TGFβ-dependent or TGFβ-independent 
pathways.
Does Lineage-Specific Variation in TGFβ 
Signaling Predispose to Aortopathy Through 
a Pathogenic TGFβ Overdrive?
Two types of aortic SMCs are found in the ascending aorta: 
cardiac neural crest (CNC)–derived VSMCs and mesoderm 
second heart field (SHF)–derived VSMCs. CNC-derived 
VSMCs show increased sensitivity to TGFβ compared with 
SHF-derived VSMCs. Lindsay and Dietz3 built on these ob-
servations and developed a new hypothesis to embrace the 
paradox of high TGFβ signaling in TAADs. According to 
this hypothesis, SHF-derived VSMCs are more sensitive to 
an alteration of TGFβ signaling compared with CNC-derived 
VSMCs. Loss of TGFβ signaling in SHF-derived VSMCs 
would initiate compensatory events leading to increased ex-
pression/accumulation of TGFβ, which, in turn, could drive 
(excessive) signaling in CNC-derived VSMCs to induce aor-
topathy.3 Despite the apparent attractiveness of the hypothesis, 
there is no actual data to support it, and there are reasons to 
think that the hypothesis is not valid. In fact, the aortic pheno-
type of mice with selective deletion of Tgfbr2 in SHF-derived 
cells,20 cited in support of the hypothesis, is different from the 
aortic phenotype of mice with deletion of Tgfbr2 in all aortic 
VSMCs. Moreover, why would abrogation of TGFβ signaling 
in CNC-derived VSMCs on top of the already defective signal-
ing in SHF-derived VSMCs (leading to abrogation of TGFβ 
signaling in all aortic root VSMCs) prevent the development 
of aortic disease? It should rather promote TAAD as described 
after deletion of Tgfbr2 signaling in all VSMC subsets.16
1720  Circulation Research  May 26, 2017
Conclusions
Fourteen years after the pathogenic TGFβ hypothesis, there is 
still insufficient evidence that MFS, LDS, or other TAADs are 
mediated by an overdrive of TGFβ signaling. In fact, most of 
the available data indicate that TGFβ is vasculoprotective in 
those settings.
We think that the concept was based on 2 disputable 
interpretations. The first one has considered increased ex-
pression of P-SMAD2/3 and TGFβ-responsive gene prod-
ucts in diseased aortas as a pathognomonic signature of 
increased TGFβ signaling and a primary mechanism in dis-
ease pathogenesis, with little attention to any other plausible 
interpretation. The second one attributed the beneficial ef-
fect of losartan in mouse models of MFS and LDS to its 
TGFβ-antagonizing properties, not considering a large body 
of evidence that showed induction or aggravation of aortic 
aneurysm and dissection after direct inhibition of TGFβ ac-
tivity or signaling.
We think that strategies aimed at inhibition of TGFβ-
dependent signaling are unlikely to provide any benefit to pa-
tients with TAADs and may even aggravate their disease. The 
time has come to abandon the unproven hypothesis of detri-
mental TGFβ overdrive in TAADs and explore new concepts 
and horizons.21,22
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